Adaptive immune responses to commensal microbes in human newborns (ADAPT-ANEW)

Horizon Europe Guarantee · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 01, 2030
Response Due
Active
Status

Opportunity Overview

Newborns are colonized by microbes at birth and during the first months of postnatal life. In order to establish symbiotic relationships with microbes, newborn immune cells must tolerate beneficial microbes, while limiting invasive pathogens (1). This ancient process, shaped by evolution, may be altered by antibiotic exposure, C-section delivery and infant formula, all of which associate with an increased risk of immune-mediated disease like allergies, asthma and inflammatory bowel disease (2). The mechanisms whereby symbiotic immune-microbe interactions are established remain poorly understood in humans. In mice, a transient immune reaction to commensals occurs after weaning, inducing regulatory T cells and tolerance which prevent immunopathology later in life (3). Whether a similar response occurs in humans early in life is not known. Interactions with commensals are also important for generating a diversified repertoire of cross-reactive lymphocytes able to recognize and respond to pathogens and vaccines.
Here I propose multimodal analyses of adaptive lymphocyte responses towards colonizing microbes early in life by single-cell analyses and antibody profiling of serial blood samples already collected from a human birth cohort (6–8). By monitoring the specificity, clonal structure and transcriptional regulation of commensal-reactive T and B cells, we hope to learn how tolerance is ensured, and colonization allowed, and how commensal-specific lymphocytes are diversified, maintained and regulated to secure long-term immune-microbe mutualism. This program holds the potential for greatly expanding our knowledge of newborn immune systems and the development of healthy immune microbe interactions, with important implications for understanding immune-mediated disease, susceptibility to infections and the protective effects of vaccines.

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHorizon Europe Guarantee
CountryUnited Kingdom
CategoryResearch Development
PublishedJanuary 01, 2025
Procurement stageActive solicitation
Response dueJanuary 01, 2030
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Heat Indicators for Global Health: Surveillance, Early Warning Systems and adaptation-mitigation actions to reduce heat impacts in pregnant women, infants and health workers in the EU and Africa (HIGH Horizons)
SEROLOGICAL TESTING AND TREATMENT FOR P. VIVAX: FROM A CLUSTER-RANDOMISED TRIAL IN ETHIOPIA AND MADAGASCAR TO A MOBILE-TECHNOLOGY SUPPORTED INTERVENTION
Support for the International Research Consortium on Animal Health (SIRCAH2)
ZEV-UP: Frugal Zero-Emission Vehicles for the Urban Passenger challenge
Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa.
GEORGE
Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival (EChiLiBRiST)
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.